New research warns that popular deep learning systems trained for cancer pathology may be relying on hidden shortcuts rather than genuine biological signals.

MRI-guided personalisation of neoadjuvant chemotherapy duration is associated with improved 3-year survival outcomes in patients with stage II-III HER2-positive breast cancer, a new trial reports.

Yale researchers have developed a machine learning model, called Immunostruct, that can help scientists create more ...

A new study from researchers at the Hebrew University of Jerusalem provides fresh insight into how pancreatic cancer may ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

To further the quantitative understanding of cellular decision making, Dr. Gregory Reeves and his team in the chemical engineering department have worked to interpret how a transcription factor ...

Photonic crystal sensor shows over 91% accuracy for cervical cancer screening, maintaining performance across varied ...

Given the success of the Research Topic "Advancing Cancer Imaging Technologies: Bridging the Gap from Research to Clinical Practice", we are pleased to ...

In the long and often dispiriting quest to cure cancer, the 1998 approval of the drug Herceptin was a tremendously hopeful moment. This drug for breast cancer was the first to use a tumor-specific ...